ArticleLeukemia2025
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.
Clifford M Csizmar et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it